Energy deprivation therapy for prostate cancer can lead to metabolic derangement, diabetes, and fatty liver disease. — Whalespan
Energy deprivation therapy for prostate cancer can lead to metabolic derangement, diabetes, and fatty liver disease.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“and the total metabolic derangement it it brings on those men so if they don't die from prostate cancer they're going to die from diabetes and yeah the complications of fatty liver disease yeah i mean they hate this disease that the therapy um”